KRP-203 Is a Desirable Immunomodulator for Islet Allotransplantation.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
pubmed:
10
7
2021
medline:
28
4
2022
entrez:
9
7
2021
Statut:
ppublish
Résumé
The current standard immunosuppressive regimens, calcineurin inhibitors, have diabetogenic and anti-vascularization effects on islet grafts. KRP-203, a sphingosine-1-phosphate functional antagonist, exerts its immunomodulatory function through lymphocyte sequestration. However, the effect of this antagonist on islets is unclear. We examined the effect of KRP-203 on the islet function and vascularization and sought a calcineurin-free regimen for islet allotransplantation. KRP-203 was administered for 14 d to mice, then diabetogenic effect was evaluated by blood glucose levels and a glucose tolerance test. Static glucose stimulation, the breathing index, and insulin/DNA were examined using isolated islets. Islet neovascularization was evaluated using a multiphoton laser scanning microscope. After islet allotransplantation with either KRP-203 alone, sirolimus alone, or both in combination, the graft survival was evaluated by blood glucose levels and immunohistochemical analyses. A mixed lymphocyte reaction was also performed to investigate the immunologic characteristics of KRP-203 and sirolimus. No significant differences in the blood glucose levels or glucose tolerance were observed between the control and KRP-203 groups. Functional assays after islet isolation were also comparable. The multiphoton laser scanning microscope showed no inhibitory effect of KRP-203 on islet neovascularization. Although allogeneic rejection was effectively inhibited by KRP-203 monotherapy (44%), combination therapy prevented rejection in most transplanted mice (83%). KRP-203 is a desirable immunomodulator for islet transplantation because of the preservation of the endocrine function and lack of interference with islet neovascularization. The combination of KRP-203 with low-dose sirolimus may be promising as a calcineurin-free regimen for islet allotransplantation.
Sections du résumé
BACKGROUND
The current standard immunosuppressive regimens, calcineurin inhibitors, have diabetogenic and anti-vascularization effects on islet grafts. KRP-203, a sphingosine-1-phosphate functional antagonist, exerts its immunomodulatory function through lymphocyte sequestration. However, the effect of this antagonist on islets is unclear. We examined the effect of KRP-203 on the islet function and vascularization and sought a calcineurin-free regimen for islet allotransplantation.
METHODS
KRP-203 was administered for 14 d to mice, then diabetogenic effect was evaluated by blood glucose levels and a glucose tolerance test. Static glucose stimulation, the breathing index, and insulin/DNA were examined using isolated islets. Islet neovascularization was evaluated using a multiphoton laser scanning microscope. After islet allotransplantation with either KRP-203 alone, sirolimus alone, or both in combination, the graft survival was evaluated by blood glucose levels and immunohistochemical analyses. A mixed lymphocyte reaction was also performed to investigate the immunologic characteristics of KRP-203 and sirolimus.
RESULTS
No significant differences in the blood glucose levels or glucose tolerance were observed between the control and KRP-203 groups. Functional assays after islet isolation were also comparable. The multiphoton laser scanning microscope showed no inhibitory effect of KRP-203 on islet neovascularization. Although allogeneic rejection was effectively inhibited by KRP-203 monotherapy (44%), combination therapy prevented rejection in most transplanted mice (83%).
CONCLUSIONS
KRP-203 is a desirable immunomodulator for islet transplantation because of the preservation of the endocrine function and lack of interference with islet neovascularization. The combination of KRP-203 with low-dose sirolimus may be promising as a calcineurin-free regimen for islet allotransplantation.
Identifiants
pubmed: 34241985
pii: 00007890-202205000-00015
doi: 10.1097/TP.0000000000003870
pmc: PMC9038237
doi:
Substances chimiques
Blood Glucose
0
Immunosuppressive Agents
0
KRP-203
0
Sulfhydryl Compounds
0
Glucose
IY9XDZ35W2
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
963-972Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Heisel O, Heisel R, Balshaw R, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004;4:583–595.
Hernández-Fisac I, Pizarro-Delgado J, Calle C, et al. Tacrolimus-induced diabetes in rats courses with suppressed insulin gene expression in pancreatic islets. Am J Transplant. 2007;7:2455–2462.
Nishimura R, Nishioka S, Fujisawa I, et al. Tacrolimus inhibits the revascularization of isolated pancreatic islets. PLoS One. 2013;8:e56799.
Maeda A, Goto M, Zhang J, et al. Immunosuppression with FTY720 and cyclosporine A inhibits rejection of adult porcine islet xenografts in rats. Transplantation. 2003;75:1409–1414.
Fujishiro J, Kudou S, Iwai S, et al. Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. Transplantation. 2006;82:804–812.
Lukas S, Patnaude L, Haxhinasto S, et al. No differences observed among multiple clinical S1P1 receptor agonists (functional antagonists) in S1P1 receptor down-regulation and degradation. J Biomol Screen. 2014;19:407–416.
Shimizu H, Takahashi M, Kaneko T, et al. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation. 2005;111:222–229.
Khattar M, Deng R, Kahan BD, et al. Novel sphingosine-1-phosphate receptor modulator KRP203 combined with locally delivered regulatory T cells induces permanent acceptance of pancreatic islet allografts. Transplantation. 2013;95:919–927.
Hou H, Cao R, Quan M, et al. Rapamycin and fingolimod modulate Treg/Th17 cells in experimental autoimmune encephalomyelitis by regulating the Akt-mTOR and MAPK/ERK pathways. J Neuroimmunol. 2018;324:26–34.
Uematsu SS, Inagaki A, Nakamura Y, et al. The optimization of the prevascularization procedures for improving subcutaneous islet engraftment. Transplantation. 2018;102:387–395.
Asami K, Inagaki A, Imura T, et al. Thioredoxin-1 attenuates early graft loss after intraportal islet transplantation in mice. PLoS One. 2013;8:e70259.
Dendo M, Maeda H, Yamagata Y, et al. Synergistic effect of neutral protease and clostripain on rat pancreatic islet isolation. Transplantation. 2015;99:1349–1355.
Goto M, Abe H, Ito-Sasaki T, et al. A novel predictive method for assessing the quality of isolated pancreatic islets using scanning electrochemical microscopy. Transplant Proc. 2009;41:311–313.
Shigeta K, Kikuchi M, Tanaka M, et al. Development of a precise quantitative method for monitoring sirolimus in whole blood using LC/ESI-MS/MS. Biomed Chromatogr. 2020;34:e4853.
Kuwabara R, Hamaguchi M, Fukuda T, et al. Long-term functioning of allogeneic islets in subcutaneous tissue pretreated with a novel cyclic peptide without immunosuppressive medication. Transplantation. 2018;102:417–425.
Nakafusa Y, Nitta N, Nakamura M, et al. Acceptance of murine islet allografts without immunosuppression in the inguinal subcutaneous white adipose tissue pretreated with bFGF. Diabetes. 2018;67(Suppl 1):32-OR.
Salvadori M, Budde K, Charpentier B, et al.; FTY720 0124 Study Group. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant. 2006;6:2912–2921.
Tedesco-Silva H, Lorber MI, Foster CE, et al. FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study. Clin Transplant. 2009;23:589–599.
Tedesco-Silva H, Mourad G, Kahan BD, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation. 2004;77:1826–1833.
Tedesco-Silva H, Szakaly P, Shoker A, et al.; FTY720 2218 Clinical Study Group. FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Transplantation. 2007;84:885–892.
Xiang Z, Ma LL, Manicassamy S, et al. CD4+ T cells are sufficient to elicit allograft rejection and major histocompatibility complex class I molecule is required to induce recurrent autoimmune diabetes after pancreas transplantation in mice. Transplantation. 2008;85:1205–1211.
Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9:883–897.
Pelz A, Schaffert H, Diallo R, et al. S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onset. Eur J Immunol. 2018;48:498–508.
Fabian MC, Lakey JR, Rajotte RV, et al. The efficacy and toxicity of rapamycin in murine islet transplantation. In vitro and in vivo studies. Transplantation. 1993;56:1137–1142.
Berney T, Secchi A. Rapamycin in islet transplantation: friend or foe? Transpl Int. 2009;22:153–161.
Han Y, Wu L, Ling Q, et al. Intestinal dysbiosis correlates with sirolimus-induced metabolic disorders in mice. Transplantation. 2021;105:1017–1029.
Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27–31.
Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA. 2005;293:830–835.
Chalasani G, Rothstein D. Non-antibody mediated roles of B cells in allograft survival. Curr Transplant Rep. 2014;1:155–165.
Durand J, Chiffoleau E. B cells with regulatory properties in transplantation tolerance. World J Transplant. 2015;5:196–208.
Deng S, Moore DJ, Huang X, et al. Cutting edge: transplant tolerance induced by anti-CD45RB requires B lymphocytes. J Immunol. 2007;178:6028–6032.
Webster KE, Walters S, Kohler RE, et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med. 2009;206:751–760.
Huang Q, Ma X, Wang Y, et al. IL-10 producing type 2 innate lymphoid cells prolong islet allograft survival. EMBO Mol Med. 2020;12:e12305.
Takuwa Y, Du W, Qi X, et al. Roles of sphingosine-1-phosphate signaling in angiogenesis. World J Biol Chem. 2010;1:298–306.
Liu Y, Wada R, Yamashita T, et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest. 2000;106:951–961.
Fischl AS, Wang X, Falcon BL, et al. Inhibition of sphingosine phosphate receptor 1 signaling enhances the efficacy of VEGF receptor inhibition. Mol Cancer Ther. 2019;18:856–867.
Kono M, Mi Y, Liu Y, et al. The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis. J Biol Chem. 2004;279:29367–29373.